Celera Product Development Will Be Emphasized Following Venter’s Exit
This article was originally published in The Gray Sheet
Executive Summary
Celera Genomics President and Chief Scientific Officer Craig Venter's decision to step down as head of the Applera Corp. subsidiary underscores Celera's shift toward drug discovery and diagnostics development and away from selling subscriptions to its genomic database